专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006059357A2 USE OF COMPOUNDS THAT INTERFERE WITH THE HEDGEHOG SIGNALING PATHWAY FOR THE MANUFACTURE OF A MEDICAMENT FOR PREVENTING, INHIBITING, AND/ OR REVERSING OCULAR DISEASES RELATED WITH OCULAR NEOVASCULARIZATION 审中-公开
标题翻译：使用与HEDGEHOG信号通道干扰用于预防，抑制和/或逆转与眼部新生血管相关的眼科疾病的药物的化合物
公开(公告)号：WO2006059357A2
公开(公告)日：2006-06-08
申请号：PCT/IT2005/000712
申请日：2005-12-02
申请人： FONDAZIONE TELETHON , AURICCHIO, Alberto , HILDINGER, Markus , SURACE, Enrico, Maria
发明人： AURICCHIO, Alberto , HILDINGER, Markus , SURACE, Enrico, Maria
IPC分类号： A61K31/00 , A61K38/00 , A61K31/445 , A61K31/4355 , A61K31/58 , A61K31/56 , A61P27/02
CPC分类号： A61K38/1709 , A61K31/00 , A61K31/4355 , A61K31/445 , A61K31/56 , A61K31/58 , C07K16/18 , C12N15/113 , C12N15/86 , C12N2310/14 , C12N2750/14143
摘要： The present invention concerns the use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/ or reversing ocular diseases related with ocular neovascularization. Particularly, the above-mentioned diseases are (wet) age-related macular degeneration, (proliferative) diabetic retinopathy, neovascular glaucoma, retinal vein occlusion, or retinopathy of prematurity (ROP).
摘要翻译：本发明涉及干扰刺猬蛋白信号传导途径的化合物在制备用于预防，抑制和/或逆转与眼睛新生血管形成相关的眼部疾病的药物中的用途。特别地，上述疾病是（湿性）年龄相关性黄斑变性，（增殖性）糖尿病性视网膜病变，新生血管性青光眼，视网膜静脉阻塞或早产儿视网膜病变（ROP）。

2. 发明申请

WO2006059357A3 USE OF COMPOUNDS THAT INTERFERE WITH THE HEDGEHOG SIGNALING PATHWAY FOR THE MANUFACTURE OF A MEDICAMENT FOR PREVENTING, INHIBITING, AND/ OR REVERSING OCULAR DISEASES RELATED WITH OCULAR NEOVASCULARIZATION 审中-公开
公开(公告)号：WO2006059357A3
公开(公告)日：2006-06-08
申请号：PCT/IT2005/000712
申请日：2005-12-02
申请人： FONDAZIONE TELETHON , AURICCHIO, Alberto , HILDINGER, Markus , SURACE, Enrico, Maria
发明人： AURICCHIO, Alberto , HILDINGER, Markus , SURACE, Enrico, Maria
IPC分类号： A61K31/00 , A61K38/00 , A61K31/445 , A61K31/4355 , A61K31/58 , A61K31/56 , A61P27/02
摘要： The present invention concerns the use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/ or reversing ocular diseases related with ocular neovascularization. Particularly, the above-mentioned diseases are (wet) age-related macular degeneration, (proliferative) diabetic retinopathy, neovascular glaucoma, retinal vein occlusion, or retinopathy of prematurity (ROP).

3. 发明申请

WO2004042024A3 COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF HIF-1 ALPHA 审中-公开
公开(公告)号：WO2004042024A3
公开(公告)日：2004-05-21
申请号：PCT/US2003/034826
申请日：2003-10-31
申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA , REICH, Samuel, Jotham , SURACE, Enrico, Maria , TOLENTINO, Michael, J.
发明人： REICH, Samuel, Jotham , SURACE, Enrico, Maria , TOLENTINO, Michael, J.
IPC分类号： C07H21/04
摘要： RNA interference using small interfering RNAs which target HIF-1 alpha mRNA inhibit expression of the HIF-1 alpha gene. As HIF-1 alpha is a transcriptional regulator of VEGF, expression of VEGF is also inhibited. Control of VEGF production through siRNA-mediated down-regulation of HIF-1 alpha can be used to inhibit angiogenesis, in particularly in diseases such as diabetic retinopathy, age related macular degeneration and many types of cancer.

4. 发明申请

WO2017137493A1 SYNTHETIC PROMOTERS AND USES THEREOF 审中-公开
标题翻译：合成促动器及其用途
公开(公告)号：WO2017137493A1
公开(公告)日：2017-08-17
申请号：PCT/EP2017/052858
申请日：2017-02-09
申请人： FONDAZIONE TELETHON
发明人： SURACE, Enrico, Maria , LUPO, Mariangela , BOTTA, Salvatore , MARROCCO, Elena , DE PRISCO, Nicola
IPC分类号： C07K14/72
CPC分类号： C07K14/00 , C12N2830/008
摘要： The present invention relates to the treatment and/or prevention of a retinal disease by using a polynucleotide promoter wherein said polynucleotide or a variant thereof consists of the sequence TCCTCCTAGTGTCACCTTGGCCCCTCTTAGAAGCCAATTAGGCCCTCAGTTTCTGCAGCGGGGATTAAT ATGATTATGAACACCCCCAATCTCCCAGATGCTGATTCAGCCAGGAGCTTAGGAGGGGGAGGTCACTT TATAAGGGTCTGGGGGGGTCAGAACCCAGAGTCATCCAGCTGGAGCCCTGAGTGGCTGAGCTCAGGC CTTCGCAGCATTCTTGGGTGGGAGCAGCCACGGGTCAGCCACAAGGGCCACAGCC (hRHOs-wt; SEQ ID NO. 1) wherein the fragment TGAACACCCCCAATCTCCCAGATGCT (sequence from nucleotide 77 to nucleotide 102 of SEQ ID NO. 1) is substituted, to the use of relative vector, vector systems, host cells and pharmaceutical compositions.
摘要翻译：
本发明涉及一种视网膜疾病的治疗和/或预防通过使用多核苷酸的启动子，其特征在于所述多核苷酸或其变体由序列TCCTCCTAGTGTCACCTTGGCCCCTCTTAGAAGCCAATTAGGCCCTCAGTTTCTGCAGCGGGGATTAAT ATGATTATGAACACCCCCAATCTCCCAGATGCTGATTCAGCCAGGAGCTTAGGAGGGGGAGGTCACTT TATAAGGGTCTGGGGGGGTCAGAACCCAGAGTCATCCAGCTGGAGCCCTGAGTGGCTGAGCTCAGGC CTTCGCAGCATTCTTGGGTGGGAGCAGCCACGGGTCAGCCACAAGGGCCACAGCC（hRHOs-重量; SEQ ID 其中片段TGAACACCCCCAATCTCCCAGATGCT（SEQ ID NO.1第77位核苷酸至第102位核苷酸的序列）被取代，用于相对载体，载体系统，宿主细胞和药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式